

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 967 214 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
29.12.1999 Bulletin 1999/52

(51) Int Cl.⁶: **C07D 487/04, A61K 31/505**

(21) Application number: **99304425.4**

(22) Date of filing: **08.06.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **22.06.1998 GB 9813452**
24.09.1998 GB 9820837
13.02.1999 GB 9903177

(71) Applicants:
• **Pfizer Limited**
Sandwich Kent CT13 9NJ (GB)
Designated Contracting States:
GB
• **Pfizer Research and**
Development Company, N.V./S.A.
Dublin 1 (IE)
Designated Contracting States:
**BE CH DE DK ES FI FR GR IE IT LI LU NL SE AT
CY**

(72) Inventors:
• **Billotte, Anne**
Sandwich, Kent, CT13 9NJ (GB)
• **Dunn, Peter James**
Sandwich, Kent, CT13 9NJ (GB)
• **Henry, Brian Thomas**
Sandwich, Kent, CT13 9NJ (GB)
• **Marshall, Peter Vallance**
Sandwich, Kent, CT13 9NJ (GB)
• **Woods, Joanna Jayne**
Sandwich, Kent, CT13 9NJ (GB)

(74) Representative: **Moore, James William**
Pfizer Limited,
European Patent Department,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **Intranasal formulations for treating sexual disorders**

(57) Intranasal formulations of sildenafil mesylate

for the treatment of male erectile dysfunction or female sexual disorders.

EP 0 967 214 A1

Description

[0001] This invention relates to intranasal formulations of cyclic guanosine 3', 5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of sexual disorders such as impotence. The invention also includes sildenafil mesylate and intranasal formulations thereof and its use in treating sexual disorders.

[0002] According to the specification of our International patent application W094/28902 we have discovered that compounds which are inhibitors of the cGMP PDE5 enzyme are potent and effective compounds for the treatment of male erectile dysfunction (MED, impotence) and for female sexual disorders. This discovery led to the development of the compound sildenafil (5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro- 1-methyl- 3-propylpyrazolo[4,3-d]pyrimidin-7-one) (VIAGRA™) which has proved to be outstandingly successful as the first orally effective treatment for MED. W098/53819 which was published on 3 December 1998 (after the priority date of the present invention) claims intranasal compositions of cGMP phosphodiesterase inhibitors, including sildenafil, for treating erectile dysfunction.

[0003] The intranasal route has previously been employed as a mode of administration for certain pharmaceutical products. The absorption rate of an agent from the nasal cavity is dependent on a number of variables; however two key factors are the surface area available for absorption and the local blood flow of the nasal cavity. The available surface area for absorption is dictated by the nasal cavity airflow resistance which is under the control of a dense capillary bed of erectile cavernous tissue in the nasal cavity. Vasodilation of these tissues leads to nasal congestion or rhinitis, for example, which increases resistance to air flow and reduces the available surface area for drug absorption. However, vasodilation can also increase bloodflow and enhance absorption by increasing the rate of removal of the drug from the site of absorption.

[0004] Vasodilation has been shown to have a wide range of effects on nasal drug absorption. Increased nasal blood flow, nasal inflammation and rhinitis have been shown to have no effect on the intranasal absorption of some agents, however these effects have also been shown to both increase and decrease the absorption of other agents. Thus, it is unclear whether vasodilation will lead to enhanced or reduced nasal absorption following intranasal dosing of a drug.

[0005] Inhibitors of the PDE5 enzyme are potent vasodilators. PDE5 has been shown to be located in the capillary bed of the nasal cavity. Inhibitors of this enzyme might therefore be expected to lead to local vasodilation and nasal congestion. Intranasal administration of a PDE5 inhibitor would be anticipated to increase local vasodilation and could cause nasal congestion.

Local increased blood flow may enhance the absorption rate of the drug but vasodilation could cause nasal congestion which may decrease the available surface area for absorption. Moreover the drug could cause local irritation. Thus the effectiveness and acceptability of this route of administration for these agents is difficult to predict.

[0006] We have surprisingly discovered that sildenafil can be successfully administered by the intranasal route and moreover the drug is surprisingly more rapidly absorbed following intranasal administration compared to the corresponding oral dose, leading to a more rapid onset of action and efficacy at lower doses. Although, as explained above PDE5 inhibitors have the potential to cause nasal congestion, this effect was not sufficient to inhibit the rapid absorption of the drug.

[0007] A further factor influencing the ability of a product to be absorbed following nasal administration is aqueous solubility. This enables the compound to dissolve in the mucosal tissue lining the nasal cavity when administered as a powder. Moreover, since only a small volume of a nasal formulation (such as an aqueous spray) can be applied, for administration as a solution, it is important to be able to achieve a sufficiently high concentration of the active ingredient to ensure that sufficient drug can be delivered to each nostril.

[0008] According to the present invention, we have discovered that one particular salt of sildenafil, sildenafil mesylate, has unexpectedly high aqueous solubility and this makes it particularly suitable for use in aqueous intranasal formulations. Sildenafil mesylate is a novel salt form of sildenafil and forms the primary aspect of this invention. We have also discovered that sildenafil mesylate forms a crystalline mono and dihydrate which have advantages in terms of their long term stability on storage and this forms a further feature of this aspect of the invention.

[0009] As well as being particularly suited to intranasal administration, sildenafil mesylate may be administered by a number of other routes where high aqueous solubility is an advantage.

[0010] Intranasal formulations are well known in the art and can either be powder formulations or more commonly nasal sprays. Such sprays typically comprise a solution of the active drug in physiological saline or other pharmaceutically suitable carrier liquids. Various nasal spray compression pumps are also well known in the art and can be calibrated to deliver a predetermined dose of the active drug.

[0011] The nasal formulations should deliver a dose of cGMP-PDE5 inhibitor of from 1 to 100mg, more preferably 5 to 20mgs per shot which can be given as one or more shots per nostril.

[0012] For solution formulations typical volumes used are 25 to 200µL, more preferably 75 to 150µL per dose in each nostril. The intranasal solution formulations can be administered as drops from a nasal dropper bottle or as aerosols after being applied from squeeze bottles,

single unit dose or metered-dose pump sprays. To avoid nasal irritation the formulations are preferably buffered to pH 3-8, more preferably 4 to 7 using standard buffer systems, such as citrate, lactate or phosphate buffers to control the pH. In addition osmolarity must be adjusted so that the formulation is isotonic using standard os-

[0013] Additional stabilisers may be required to improve chemical stability of the formulations; i.e. anti-oxidants such as sodium metabisulfite, sodium bisulfite or tocopherol, or metal chelators such as ethylenediamine-tetraacetic acid.

[0014] Single unit-dose spray can be prepared aseptically or terminally sterilised to produce a sterile final product. Alternatively, multi-dose metered valve pump systems can be maintained free of microbial contamination with the use of chemical preservatives (e.g. benzalkonium chloride or benzyl alcohol).

[0015] Flavouring, perfumes and humectants may also be added to improve the patient acceptability of the formulations.

[0016] One particular and preferred formulation comprises a solution of the active cGMP PDE5 inhibitor in 5% weight/volume aqueous glycerine.

[0017] In another particular and preferred aspect of the invention we have discovered that by using a solubility enhancer it is possible to further improve the aqueous solubility of sildenafil mesylate. Examples of suitable solubility enhancers include xanthines (e.g. caffeine), vitamins (e.g. nicotinamide) and pharmaceutical excipients (e.g. vanillin and benzyl alcohol). Combination of any of these agents is also possible.

[0018] Preferred as solubility enhancing agents are caffeine (preferably at a concentration of from 1.0 to 2.5% weight/vol); nicotinamide (preferably 3.0 to 20.0% weight/vol); vanillin (preferably 0.5 to 2.5% weight/vol); and benzyl alcohol (preferably 0.5 to 2.5% weight/vol). A combination of nicotinamide and vanillin is also preferred. By using such solubility enhancing agents, it is possible to increase the solubility of sildenafil mesylate in water from approximately 60 mg/ml to in excess of 100 mg/ml. This allows a more concentrated solution to be administered facilitating a rapid onset of action and reducing irritancy. One particular and preferred formulation comprises sildenafil mesylate 100 mg/ml and caffeine 15 mg/ml in a buffered aqueous solution. The pH of the solution is preferably adjusted to pH 3-5, preferably to pH 4.2 by the addition of a base e.g. sodium hydroxide.

[0019] The formulations are conveniently prepared by dissolving sildenafil mesylate, the solubility enhancer and buffer in water, adjusting the pH if necessary, sterilising by filtration or autoclave and aseptically filling into spray bottles or other dispensers. Alternatively sildenafil free base can be added to an aqueous solution of methanesulphonic acid and solubility enhancer (eg caffeine), stirred until dissolved, buffer added and the pH adjusted prior to sterilising and filling as before.

[0020] Powder formulations can overcome stability issues associated with liquid formulations and are not limited by solubility, thus higher doses can be delivered into the nasal cavity. Sildenafil mesylate can be formulated as powder formulation to be insufflated into the nose utilising specialised drug delivery devices (available from commercial manufacturers such as Mait Spa, Italy; Valois SA, France; Pfeiffer, Germany or Orion, Finland). The powder can be placed in hard gelatine capsules, foil blisters or as an integral part of the device for delivery of single unit doses. Alternatively, multi-dose dry powder systems are also available.

[0021] The particle size of the powder is an important factor for successful delivery to the nasal cavity. Powders with particle size $<1\mu\text{m}$ tend to be carried through the nose and inhaled into the lungs, whereas larger particles may not have a sufficient dissolution rate to allow absorption during the short nasal residence time. Preferred particle size distribution for powder formulations in accordance with the present invention is 1 - 100 μm , more preferably 5 - 40 μm .

[0022] In addition, carrier powders such as lactose and dextrose are often blended with the drug powder to aid manufacture and dose reproducibility on intranasal administration.

[0023] Thus the invention also includes an intranasal pharmaceutical formulation for the treatment of male erectile dysfunction or female sexual disorders which comprises sildenafil mesylate together with a pharmaceutically acceptable diluent or carrier in a form adapted for intranasal administration.

[0024] The effectiveness of the intranasal formulations of the present invention were evaluated in dogs. Four fasted dogs were lightly anaesthetised, each received 5mg of the cGMP-PDE5 inhibitor in both nostrils. The drug was administered both as a powder and as a solution. Plasma levels of the active agent were measured and compared with plasma levels obtained when the dogs were previously orally dosed with the agent.

[0025] Results from these studies showed that intranasal administration of sildenafil led to a rapid and significantly higher blood plasma levels than obtained following oral administration. Sildenafil mesylate was particularly effective.

[0026] Thus a solution dose of 0.7mg/kg of sildenafil mesylate administered by the intranasal route to four dogs gave a mean peak blood plasma levels of 407ng/ml after a period of 5 minutes. This can be compared with an oral dose of 1.4mg/kg of sildenafil citrate which gave mean peak blood plasma levels of 204ng/ml after 136 minutes.

[0027] These findings have been confirmed in man where studies in volunteers have shown that blood plasma levels of sildenafil comparable with oral dosing can be obtained following intranasal administration of sildenafil mesylate, with peak blood plasma levels occurring 5-15 minutes after administration.

[0028] The following examples, illustrate preparation

of the formulations of the invention as well as the preparation of sildenafil mesylate and the crystalline hydrates thereof.

EXAMPLE 1

INTRANASAL SOLUTION FORMULATIONS

[0029] Intranasal solution formulations were prepared of the following composition:

1.	Sildenafil mesylate	to	50mg
	Water for injections		1 mL.
2.	Sildenafil mesylate		50mg
	Glucose		50mg
	Water for injection	to	1 mL
3.	Sildenafil mesylate		50mg
	Glucose		50mg
	Benzyl alcohol		10mg
	Water for injections	to	1mL
4.	Sildenafil mesylate		25mg
	5% w/v aqueous glycerine	to	1mL
5.	Sildenafil mesylate		50mg
	5% w/v aqueous glycerine	to	1mL

[0030] The solutions were aseptically filtered and filled into plastic nasal spray bottles.

EXAMPLE 2

INTRANASAL SOLUTION FORMULATION

[0031] A solution was prepared containing the following:

Sildenafil mesylate	10g
Caffeine	1.5g
Sodium dihydrogen phosphate	0.69g
Distilled water	to 100ml

[0032] The solution was stirred to dissolve the ingredients and the pH adjusted to 4.2 by the addition of 1M sodium hydroxide solution. The solution was sterilised by ultrafiltration or by autoclave at 120°C for 20 minutes and the cooled solution was aseptically filled into monodose nasal spray devices to deliver a unit dose of 100 microlitres.

[0033] Compositions were similarly prepared using nicotinamide (5.0g); vanillin (1.5g) or benzyl alcohol (1.5g) instead of caffeine.

EXAMPLE 3

INTRANASAL POWDER FORMULATIONS

[0034] Intranasal powder formulation was prepared of the following composition:

Sildenafil Mesylate	5mg(A)
Lactose	35mg

[0035] The composition was milled to an average particle size of 20µm and filled into a gelatin capsule for use with a commercial nasal insufflator.

EXAMPLE 4

Preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo [4,3-d]pyrimidin-7-one methanesulphonate salt (sildenafil mesylate)

[0036] 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo [4,3-d]pyrimidin-7-one¹ (100g, 0.21 mol) was dissolved in boiling acetone (3000 ml). Methanesulphonic acid (14.9 ml, 0.23 mol) was added to the hot acetone solution. Within 10 seconds a precipitate formed. The mixture was allowed to cool and granulate for 48 hours. The title product was collected by filtration and dried in vacuum to give a white crystalline solid (116.0g, 96.8%), m. p. 272-274°C.

Found: C, 48.33; H, 5.99; N, 14.68. C₂₃H₃₄N₆O₇S₂ requires C, 48.41; H, 6.00; N, 14.73 % δ (CD₃SOCD₃)² 0.92 (3H, t), 1.33 (3H, t), 1.73 (2H, heptet), 2.29 (3H, s), 2.77 (2H, t), 2.79 (3H, s), 3.16 (2H, br), 3.3-3.57 (4H, br), 3.8 (2H, br), 4.16 (3H, s), 4.20 (2H, q), 7.4 (1H, d), 7.88 (1H, dd), 7.90 (1H, s), 9.44 (1H, br).

EXAMPLE 5

Preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo [4,3-d]pyrimidin-7-one methanesulphonate dihydrate (sildenafil mesylate dihydrate).

[0037] 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo [4,3-d]pyrimidin-7-one¹ (100g, 0.21mol) was dissolved in 2-butanone (1500 ml) at 55°C and heated to reflux. A solution of methanesulphonic acid (14.9 ml, 0.23 mol) in water (75 ml) was added to the hot 2-butanone solution. After 20 minutes a precipitate formed. The mixture was allowed cool and granulate at ambient temperature for 6 hours. The title product was collected by filtration and air dried to give a white crystalline solid (119.5g, 93.5%). This material dehydrates on heating in a melting

point apparatus to give the anhydrous form which melts at 272-274°C. A small sample was carefully dried for nmr and Karl Fischer analysis.

[0038] Found: δ (CD_3SOCD_3)² 0.93 (3H, t), 1.33 (3H, t), 1.73 (2H, sextet), 2.29 (3H, s), 2.62 (2H, br), 2.76 (2H, t), 2.79 (3H, s), 3.15 (2H, br), 3.29 (HDO peak), 3.45 (2H, br), 3.78 (2H, br), 4.15 (3H, s), 4.21 (2H, q), 7.4 (1H, d), 7.9 (1H, s), 7.8 (H, dd), 9.43 (1H, br), 12.21 (1H, s). Water content (by Karl Fischer)³ = 6.7 % (theoretical for dihydrate = 5.93%)

1. Prepared as described in US patent 5,250,534 and European Patent 0463756
2. The nmr data was obtained on a Varian Unity 300 Spectrometer which was operating at 300 MHz.
3. Karl Fischer data was obtained from a Metrohm 701 KF Titrino Instrument.

EXAMPLE 6

Preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo [4,3-d]pyrimidin-7-one) methanesulphonate monohydrate (sildenafil mesylate monohydrate).

[0039] Anhydrous 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo[4,3-d]pyrimidin-7-one) methanesulphonate (1.082g) was suspended in a solution of acetone (19.4 ml) and water (0.6 ml). The suspension was allowed to stir for 1 week at room temperature and a further 55 microlitres of water added, followed a few days later by 30 microlitres of water and then 15 microlitres of water. The crystalline monohydrate product was collected by filtration and air dried (yield 0.848 mg; 84%). Thermogravimetric analysis showed a loss of 1.21% weight to 80°C followed by a further loss of 1.76% to 125°C consistent with a monohydrate product.

Claims

1. An intranasal pharmaceutical formulation for the treatment of male erectile dysfunction or female sexual disorders which comprises sildenafil mesylate, together with a pharmaceutically acceptable diluent or carrier in a form adapted for intranasal administration.
2. An intranasal formulation as claimed in claim 1 in the form of an aqueous solution or powder formulation.
3. An intranasal formulation as claimed in claim 1 comprising sildenafil mesylate in 5% weight/volume aqueous glycerine.

4. An intranasal formulation as claimed in claim 1 comprising sildenafil mesylate and caffeine in a buffered aqueous solution.
5. An intranasal formulation as claimed in claim 4 comprising sildenafil mesylate 100mg/ml and caffeine 15mg/ml, in an aqueous solution buffered to pH4.2.
6. An intranasal powder formulation as claimed in claim 1 comprising sildenafil mesylate having a particle size of from 5 to 40 micrometres optionally with a pharmaceutically acceptable carrier.
7. An intranasal pharmaceutical presentation comprising sildenafil mesylate together with a pharmaceutically acceptable diluent or carrier as claimed in any one of claims 1 to 6 in an intranasal delivery system or device.
8. A method of treating male erectile dysfunction or female sexual disorders which comprises intranasal administration of an effective amount of sildenafil mesylate.
9. Sildenafil mesylate.
10. Sildenafil mesylate, crystalline mono or dihydrate.

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 4425

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 6)
E	WO 99 27905 A (WATTS PETER JAMES ; DANBIOSYST UK (GB); ILLUM LISBETH (GB)) 10 June 1999 (1999-06-10) * page 1, line 20; claim 20 *	1-8	C07D487/04 A61K31/505
D, A	WO 94 28902 A (PFIZER LTD ; PFIZER (US); PFIZER RES & DEV (IE); ELLIS PETER (GB);) 22 December 1994 (1994-12-22) * page 1, line 1 - page 2, line 32 * * page 7, line 1-3 * * page 7, line 29 - page 12, line 4 *	1-8	
A	WO 95 05172 A (ZONAGEN INC) 23 February 1995 (1995-02-23)	1-8	
D, P, A	DATABASE WPI Section Ch, Week 199905 Derwent Publications Ltd., London, GB; Class B02, AN 1999-059770 XP002119443 & WO 98 53819 A (MOCHIDA PHARM CO LTD), 3 December 1998 (1998-12-03) * abstract *	1-8	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl. 6)
			A61K
Place of search MUNICH		Date of completion of the search 19 October 1999	Examiner Engl, B
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 (04/92) (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 4425

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-10-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9927905	A	10-06-1999	AU 1253599 A	16-06-1999
WO 9428902	A	22-12-1994	AT 163852 T	15-03-1998
			AU 676571 B	13-03-1997
			AU 6797394 A	03-01-1995
			CA 2163446 A,C	22-12-1994
			CN 1124926 A	19-06-1996
			CZ 9503242 A	17-07-1996
			DE 69408981 D	16-04-1998
			DE 69408981 T	02-07-1998
			DK 702555 T	06-04-1998
			EP 0702555 A	27-03-1996
			ES 2113656 T	01-05-1998
			FI 955911 A	08-12-1995
			GR 3026520 T	31-07-1998
			IL 109873 A	27-12-1998
			IL 121836 A	27-12-1998
			JP 2925034 B	26-07-1999
			JP 9503996 T	22-04-1997
			LV 12269 A	20-05-1999
			NO 954757 A	24-11-1995
			NZ 266463 A	24-03-1997
			PL 311948 A	18-03-1996
			ZA 9404018 A	08-12-1995
WO 9505172	A	23-02-1995	AT 174795 T	15-01-1999
			AU 696815 B	17-09-1998
			AU 7523894 A	14-03-1995
			AU 9716898 A	04-03-1999
			BR 9407250 A	24-09-1996
			CA 2169071 A	23-02-1995
			CN 1128950 A	14-08-1996
			DE 69415535 D	04-02-1999
			DE 69415535 T	17-06-1999
			EP 0714300 A	05-06-1996
			ES 2127409 T	16-04-1999
			GR 3029500 T	28-05-1999
			JP 9501677 T	18-02-1997
			NO 960549 A	12-04-1996
			NZ 271567 A	19-12-1997
			US 5565466 A	15-10-1996
			ZA 9406123 A	20-03-1995
WO 9853819	A	03-12-1998	AU 7454898 A	30-12-1998

EPO FORM P469

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)